Authors:
Howie, SEM
Fernandes, ML
Heslop, I
Hewson, TJ
Cotton, GJ
Moore, MJ
Innes, D
Ramage, R
Harrison, DJ
Citation: Sem. Howie et al., A functional, discontinuous HIV-1 gp120 C3/C4 domain-derived, branched, synthetic peptide that binds to CD4 and inhibits MIP-1 alpha chemokine binding, FASEB J, 13(3), 1999, pp. 503-511
Authors:
Moore, MJ
Winquist, EW
Murray, N
Tannock, IF
Huan, S
Bennett, K
Walsh, W
Seymour, L
Citation: Mj. Moore et al., Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada clinical trials group, J CL ONCOL, 17(9), 1999, pp. 2876-2881
Citation: T. Muzzammil et al., Tc-99(m)-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer, NUCL MED C, 20(2), 1999, pp. 115-122
Citation: Ds. Poche et al., An unconventional method for purifying the N-carboxyanhydride derivatives of gamma-alkyl-L-glutamates, SYN COMMUN, 29(5), 1999, pp. 843-854
Authors:
Bjarnason, GA
Cripps, C
Goel, R
Fine, S
Oza, AM
Skillings, JR
Kerr, I
Germond, CJ
Moore, MJ
Maroun, JA
Franssen, E
Dulude, H
Citation: Ga. Bjarnason et al., Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate,and long-term oral etoposide (FLAME) in unresectable or metastatic gastriccancer, AM J CL ONC, 21(6), 1998, pp. 537-542